$HOWL
Werewolf Therapeutics, Inc. Stock $howl

$howl Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000178553022000014 Filed on March 24, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.82M	$2.106M	$5.760M
YoY Change	157.26%		60.0%
% of Gross Profit
Research & Development	$35.27M	$5.290M	$16.64M
YoY Change	111.94%		162.48%
% of Gross Profit
Depreciation & Amortization	$216.0K	$44.00K	$150.0K
YoY Change	44.0%		400.0%
% of Gross Profit
Operating Expenses	$50.09M	$7.392M	$22.40M
YoY Change	123.56%		125.39%
Operating Profit	-$50.09M		-$22.40M
YoY Change	123.56%
Interest Expense	$104.0K	$28.00K	$100.0K
YoY Change	4.0%		-127.03%
% of Operating Profit
Other Income/Expense, Net	$104.0K	-$38.00K	$7.364M
YoY Change	-98.59%		12173.33%
Pretax Income	-$49.98M	-$7.402M	-$15.04M
YoY Change	232.33%		46.73%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$49.98M	-$7.402M	-$15.04M
YoY Change	232.33%		46.73%
Net Earnings / Revenue
Basic Earnings Per Share	-$10.94		-$28.08
Diluted Earnings Per Share	-$10.94	-$268.8K	-$28.08
COMMON SHARES
Basic Shares Outstanding	18.46M shares		1.005M shares
Diluted Shares Outstanding	18.46M shares		1.005M shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$157.5M		$92.57M
YoY Change	70.18%		417.15%
Cash & Equivalents	$157.5M	$92.57M	$92.57M
Short-Term Investments
Other Short-Term Assets	$3.537M		$340.0K
YoY Change	940.29%		100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$161.1M	$92.91M	$92.91M
YoY Change	73.36%		414.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.33M	$651.0K	$3.120M
YoY Change	423.24%		-8.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.857M	$0.00	$360.0K
YoY Change	415.83%		71.43%
Total Long-Term Assets	$18.18M	$3.484M	$3.490M
YoY Change	420.97%		-3.59%
TOTAL ASSETS
Total Short-Term Assets	$161.1M	$92.91M	$92.91M
Total Long-Term Assets	$18.18M	$3.484M	$3.490M
Total Assets	$179.3M	$96.40M	$96.40M
YoY Change	85.94%		344.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.037M	$1.021M	$1.020M
YoY Change	99.71%		61.9%
Accrued Expenses	$9.837M	$3.586M	$3.590M
YoY Change	174.01%		337.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00		$0.00
YoY Change
Long-Term Debt Due			$680.0K
YoY Change			13.33%
Total Short-Term Liabilities	$11.87M	$5.284M	$5.280M
YoY Change	124.89%		158.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00		$1.860M
YoY Change	-100.0%		-81.1%
Other Long-Term Liabilities	$14.59M	$31.00K	$30.00K
YoY Change	48530.0%		50.0%
Total Long-Term Liabilities	$14.59M	$31.00K	$1.890M
YoY Change	671.9%		-80.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.87M	$5.284M	$5.280M
Total Long-Term Liabilities	$14.59M	$31.00K	$1.890M
Total Liabilities	$26.46M	$7.179M	$7.180M
YoY Change	268.57%		-39.71%
SHAREHOLDERS EQUITY
Retained Earnings		-$51.87M
YoY Change
Common Stock		$2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$152.8M	-$51.86M	$89.22M
YoY Change
Total Liabilities & Shareholders Equity	$179.3M	$96.40M	$96.40M
YoY Change	85.94%		344.65%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$49.98M	-$7.402M	-$15.04M
YoY Change	232.33%		46.73%
Depreciation, Depletion And Amortization	$216.0K	$44.00K	$150.0K
YoY Change	44.0%		400.0%
Cash From Operating Activities	-$42.88M	-$6.009M	-$18.62M
YoY Change	130.22%		95.22%
INVESTING ACTIVITIES
Capital Expenditures	$498.0K	-$9.000K	$560.0K
YoY Change	-11.07%		-307.41%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$498.0K	-$9.000K	-$560.0K
YoY Change	-11.07%		107.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$109.4M	71.88M	$93.86M
YoY Change	16.59%		328.38%
NET CHANGE
Cash From Operating Activities	-$42.88M	-6.009M	-$18.62M
Cash From Investing Activities	-$498.0K	-9.000K	-$560.0K
Cash From Financing Activities	$109.4M	71.88M	$93.86M
Net Change In Cash	$66.05M	65.86M	$74.67M
YoY Change	-11.54%		517.13%
FREE CASH FLOW
Cash From Operating Activities	-$42.88M	-$6.009M	-$18.62M
Capital Expenditures	$498.0K	-$9.000K	$560.0K
Free Cash Flow	-$43.37M	-$6.000M	-$19.18M
YoY Change	126.09%		106.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001785530
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40366
CY2021	dei	Entity Registrant Name EntityRegistrantName	WEREWOLF THERAPEUTICS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3523180
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	1030 Massachusetts Avenue
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02138
CY2021	dei	City Area Code CityAreaCode	617
CY2021	dei	Local Phone Number LocalPhoneNumber	952‑0555
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	HOWL
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	201872133	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27653671	shares
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	157531000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92570000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3537000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	344000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	161068000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	92914000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2913000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	651000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1208000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	207000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13412000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2471000	USD
CY2021Q4	howl	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	0	USD
CY2020Q4	howl	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	155000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	649000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2021Q4	us-gaap	Assets Assets	179250000	USD
CY2020Q4	us-gaap	Assets Assets	96398000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2037000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1021000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8765000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3586000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1072000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	677000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11874000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5284000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14589000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1864000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	31000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	26463000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	7179000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	193500000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27608000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1746000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27313000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1184000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	405680000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-252895000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51865000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35269000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	152787000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-51863000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	179250000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96398000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16641000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14818000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5763000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	50087000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	22404000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-50087000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-22404000	USD
CY2021	howl	Increase Decrease In Fair Value Of Temporary Equity Liability IncreaseDecreaseInFairValueOfTemporaryEquityLiability	0	USD
CY2020	howl	Increase Decrease In Fair Value Of Temporary Equity Liability IncreaseDecreaseInFairValueOfTemporaryEquityLiability	7301000	USD
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	104000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	63000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	104000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7364000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-49983000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15040000	USD
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	151942000	USD
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	13177000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-201925000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-201925000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28217000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-28217000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.94
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.94
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-28.08
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-28.08
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18455000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18455000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1005000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1005000	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-24304000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	13177000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	632000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26000	USD
CY2020	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15040000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-51863000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2379000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	109221000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	151942000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	293024000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4095000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	235000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-49983000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	152787000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-49983000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15040000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4095000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	632000	USD
CY2021	us-gaap	Depreciation Depreciation	216000	USD
CY2020	us-gaap	Depreciation Depreciation	150000	USD
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	519000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	627000	USD
CY2021	howl	Increase Decrease In Fair Value Of Temporary Equity Liability IncreaseDecreaseInFairValueOfTemporaryEquityLiability	0	USD
CY2020	howl	Increase Decrease In Fair Value Of Temporary Equity Liability IncreaseDecreaseInFairValueOfTemporaryEquityLiability	7301000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3072000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	177000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	649000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1007000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	388000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5263000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2616000	USD
CY2021	howl	Increase Decrease In Operating Lease Liability And Right Of Use Asset IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset	-241000	USD
CY2020	howl	Increase Decrease In Operating Lease Liability And Right Of Use Asset IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset	-527000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-31000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	8000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42876000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18624000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	498000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	560000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-498000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-560000	USD
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	155000	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	111600000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2378000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	184000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	205000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	109427000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	93857000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	66053000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	74673000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92777000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18104000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158830000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92777000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1035000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	844000	USD
CY2021	howl	Stock Option Exercise Receivables In Prepaid Expenses And Other Current Assets StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets	30000	USD
CY2020	howl	Stock Option Exercise Receivables In Prepaid Expenses And Other Current Assets StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets	0	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	79000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021	howl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2020	howl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	154000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13658000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021	us-gaap	Accretion Expense AccretionExpense	151942000	USD
CY2020	us-gaap	Accretion Expense AccretionExpense	13177000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	157500000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, the fair values of common stock and redeemable convertible preferred stock and the fair value of the preferred stock tranche rights. Actual results could differ from those estimates.</span></div>
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk and Off-Balance Sheet RiskFinancial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents. Cash is held in a checking account at two financial institutions. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.
CY2021Q4	howl	Concentrations Of Credit Risk Number Of Financial Institutions ConcentrationsOfCreditRiskNumberOfFinancialInstitutions	2	institution
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	48675140	shares
CY2019Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	7800000	USD
CY2019Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	7300000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	1300000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3304000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	826000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	391000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	175000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2913000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	651000	USD
CY2021	us-gaap	Depreciation Depreciation	216000	USD
CY2020	us-gaap	Depreciation Depreciation	150000	USD
CY2021Q4	howl	Accrued Manufacturing Current AccruedManufacturingCurrent	3427000	USD
CY2020Q4	howl	Accrued Manufacturing Current AccruedManufacturingCurrent	1741000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2200000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	990000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	433000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	654000	USD
CY2021Q4	howl	Accrued Contract Research Current AccruedContractResearchCurrent	2542000	USD
CY2020Q4	howl	Accrued Contract Research Current AccruedContractResearchCurrent	107000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	163000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	94000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8765000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3586000	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3325000	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20398000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4095000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	632000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	14800000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1312000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	877000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	398000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	208000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	411000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2021	us-gaap	Lease Cost LeaseCost	2121000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1085000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y7M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.081
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.093
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2494000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21422000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3138000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2511000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2343000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2409000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	8527000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5761000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15661000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.057
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.099
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.272
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.420
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.018
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.017
CY2021	howl	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	0.000
CY2020	howl	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	0.000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.009
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.008
CY2021	howl	Effective Income Tax Rate Reconciliation Cancellation Of Tranche Rights EffectiveIncomeTaxRateReconciliationCancellationOfTrancheRights	0.000
CY2020	howl	Effective Income Tax Rate Reconciliation Cancellation Of Tranche Rights EffectiveIncomeTaxRateReconciliationCancellationOfTrancheRights	0.102
CY2021	howl	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.004
CY2020	howl	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22831000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10363000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1918000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1021000	USD
CY2021Q4	howl	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	4393000	USD
CY2020Q4	howl	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	731000	USD
CY2021Q4	howl	Deferred Tax Assets Capitalized Costs Net Of Amortization DeferredTaxAssetsCapitalizedCostsNetOfAmortization	111000	USD
CY2020Q4	howl	Deferred Tax Assets Capitalized Costs Net Of Amortization DeferredTaxAssetsCapitalizedCostsNetOfAmortization	124000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	658000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	264000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30411000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12503000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26110000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11776000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4301000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	727000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3762000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	711000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	12000	USD
CY2021Q4	howl	Deferred Tax Liabilities Construction In Progress DeferredTaxLiabilitiesConstructionInProgress	533000	USD
CY2020Q4	howl	Deferred Tax Liabilities Construction In Progress DeferredTaxLiabilitiesConstructionInProgress	0	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	4000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4301000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	727000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14300000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6700000	USD
CY2021Q4	howl	Operating Loss Carryforwards Not Subject To Expiration OperatingLossCarryforwardsNotSubjectToExpiration	80200000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3620000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20960000	shares

Files In Submission

Name	View Source	Status
0001785530-22-000014-index-headers.html	Edgar Link	pending
0001785530-22-000014-index.html	Edgar Link	pending
0001785530-22-000014.txt	Edgar Link	pending
0001785530-22-000014-xbrl.zip	Edgar Link	pending
a12312021ex231.htm	Edgar Link	pending
a12312021ex311.htm	Edgar Link	pending
a12312021ex312.htm	Edgar Link	pending
a12312021ex321.htm	Edgar Link	pending
a12312021ex43.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
howl-20211231.htm	Edgar Link	pending
howl-20211231.xsd	Edgar Link	pending
howl-20211231_cal.xml	Edgar Link	unprocessable
howl-20211231_def.xml	Edgar Link	unprocessable
howl-20211231_g1.jpg	Edgar Link	pending
howl-20211231_g2.jpg	Edgar Link	pending
howl-20211231_g3.jpg	Edgar Link	pending
howl-20211231_g4.jpg	Edgar Link	pending
howl-20211231_g5.jpg	Edgar Link	pending
howl-20211231_g6.jpg	Edgar Link	pending
howl-20211231_htm.xml	Edgar Link	completed
howl-20211231_lab.xml	Edgar Link	unprocessable
howl-20211231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HOWL
Werewolf Therapeutics, Inc. Stock $howl

2021 Form 10-K Financial Statement

#000178553022000014 Filed on March 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOWL Werewolf Therapeutics, Inc. Stock $howl

2021 Form 10-K Financial Statement

#000178553022000014 Filed on March 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOWL
Werewolf Therapeutics, Inc. Stock $howl